Late entry of 10 year old constipation drug into domestic market
A Takeda Pharmaceutical’s chronic idiopathic constipation therapy is expected to land in Korea after the 10th anniversary for its global approval.
On the 18th, the Ministry of Food and Drug Safety(MFDS) announced ‘Lubiprostone Cap(global product name: Amitiza),’ a Takeda’s chronic constipation d...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
